No Data
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $289
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $162
Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200
Express News | Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $200
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Unlock the Full List
factors that put the rise on are not from a rebound but from news, either way the price is above the price before financial reporting
